Pg-txl Company, L.p.

University of Texas System

Emerson Process Management Regulator Technologies, Inc.

Chun Li

Sidney Wallace

David J Yang

Dong-Fang Yu

Li-Ren Kuang

Roy Ronald Pelfrey

Wei Wang

Anil K Sood

Eric Alan Miller

Horatiu Petru Tripon

G Glynn Crutsinger

Richard Li

Michael Wallace

Jason Fleming

Zuxing Kan

Chiyi Xiong

Dapeng Zhou

Yunfei Wen

Shi Ke

Wayne Tansey

Jun Zhao

Chusilp Charnsangavej

Matthew W Hanusa

Sydney Wallace

Provided herein are therapeutic peptides. In some aspects, therapeutic peptides are provided that can alter EphB4/EFNB2 signaling and can be used to treat a cancer. In some embodiments, the peptides are comprised in nanoparticles, such as core-cross-linked polymeric micelles (CCPM).

Therapeutic peptides

A system for urine analysis and personal health monitoring includes a testing box, including a testing chamber, a camera aperture, a visual check aperture, and a test slot, an interchangeable color pattern chart, including a bar code, a base color calibration strip, a test result area, and a test lookup area; a diagnostic analysis server, and a diagnostic analysis device, including a processor, a diagnostic manager, a camera manager, an image analyzer, a camera calibrator, and a camera; such that the diagnostic analysis device captures an original image of the testing chamber interior with a test strip inserted, and analyzes a diagnostic portion of the original image and calculates a test result. Also disclosed is a method for diagnostic analysis, including installing interchangeable color pattern chart, depositing sample, inserting test strip, capturing image, performing color calibration, reading bar code, extracting test strip image, performing color conversion, and calculating test result.

System and method for urine analysis and personal health monitoring

Provided are compositions and nanoparticle formulations that may be used, e.g., to deliver a therapeutic compound to a subject. In some embodiments, the nanoparticles may be used to deliver one or more chemotherapeutic agents to treat a cancer such, e.g., as a pancreatic ductal adenocarcinoma.

Polymeric drug delivery systems for treatment of disease

A fluid control device has a body, actuator, and slam-shut device. The body defines an inlet, an outlet, and a plurality of slam-shut openings, and a seat is positioned along a flow path between the inlet and outlet. The actuator is configured to modulate a position of a first control element relative to a first side of the seat along an actuation axis to control a fluid pressure. The slam-shut device has a second control element that is movable along the actuation axis and is biased toward a second side of the seat and a slam-shut actuator configured to trigger the second control element to move to the closed position in which the second control element contacts the second side of the seat. The slam-shut actuator includes a shaft and the slam-shut actuator and shaft are positionable in any one of the plurality of slam-shut openings in different configurations.

Fluid-regulator with field convertible slam-shut device

A composition for stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells includes a glycolipid antigen and a nanoparticle conjugated with the glycolipid antigen. The glycolipid antigen and the nanoparticle are not antigenic in mouse and human being. The composition can further include covalent or non-covalent connection between the glycolipid antigen and the nanoparticle. The glycolipid antigen is alpha-galactosylceramide or an analog of that. The nanoparticle can be a polymer. A production method of the composition includes preparing a nanoparticle and a glycolipid antigen and loading the glycolipid antigen to the nanoparticle. The glycolipid antigen can be coated onto the surface of the nanoparticle or encapsulated within the nanoparticle. A method of stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells is also provided.

Nanoparticle formulated glycolipid antigens for immunotherapy

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

Water soluble paclitaxel prodrugs

The present invention relates to novel cyclic peptides that may be conjugated with imaging agents, including novel imaging agents. Specifically, it includes c(KRGDf; SEQ ID NO. 3) NIR imaging compositions and novel cyclic HWGFTL (SEQ ID NO. 5) polypeptides which may be used inter alia in NIR, MRI and nuclear imaging as well as therapy. Additionally, the invention includes novel imaging agents, such as TS-ICG derivatives. The invention also relates to methods of making and using such compounds. Such uses include both pre-operative and intraoperative detection of tumor cells and treatment monitoring.

Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy

The present invention concerns a design for dendritic poly(amino acid) polymer carriers, also known as nonlinear polymers, and their applications. These dendritic poly(amino acid) carriers have multiple functional groups at the polymer surface. In addition, they have heterofunctional groups on the poly(amino acid) side chains for drug or diagnostic agent attachment. They are designed to allow sufficient preservation of the binding affinity of the targeting ligand while conjugating therapeutic or diagnostic agents to the polymers. The present invention also describes methods of production of the polymer carriers and methods for the treatment or diagnosis of diseases employing the polymer carriers. The present invention also includes methods to introduce targeting moieties site-specifically to the end of polymer chains.

Dendritic poly (amino acid) carriers and methods of use

Water soluble paclitaxel derivatives

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble chelator, polyethylene glycol or polymer such as poly (1-glutamic acid) or poly (1-aspartic acid). Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis and for prediction of paclitaxel uptake by tumors and radiolabeled DTPA-paclitaxel tumor imaging. Other embodiments include the coating of implantable stents for prevention of restenosis.

Growing community of inventors

Missouri City, TX, United States of America

Chun Li